L'Oreal's CEO Says Ozempic Is Quietly Eating Into Its Skincare Sales
Nicolas Hieronimus told investors that GLP-1 weight-loss drugs are reshaping beauty spending, and the company already has a product line aimed at the side effects.
L'Oreal CEO Nicolas Hieronimus told investors Thursday that the rise of GLP-1 weight-loss drugs is doing something beauty companies did not expect: shrinking skincare demand. He called it "a very important phenomenon for us," and said SkinCeuticals already makes products designed to work alongside GLP-1 drugs, specifically targeting side effects like skin sagging.
Chief innovation officer Delphine Viguier-Hovasse told Reuters separately that L'Oreal is actively testing products on GLP-1 users, calling the group an increasingly important consumer segment. The phenomenon has a nickname now, "Ozempic face," and L'Oreal is not the only one chasing it: Galderma and Natura are studying their own products for the same facial volume loss. The timing is notable given L'Oreal's own numbers: Q3 sales rose 7.7% to 11.56 billion euros, with skincare still accelerating overall, just not as fast as it would without a few million people on Ozempic.
A drug meant to shrink waistlines is now reshaping skincare shelves, and L'Oreal's answer is to sell the cream for the problem the shot caused. Call it vertical integration for the GLP-1 economy.
Source: Business Standard
Kyle Duford, Founder & Editor, BRNDWIRE. More from Kyle →
The Brand Briefing
Liked this? Get five more every morning.
The Brand Briefing: the stories moving brands, in your inbox at 7am your time. Free.
